J Korean Neurol Assoc.
2019 May;37(2):171-173. 10.17340/jkna.2019.2.9.
Improved Bulbar Function in Amyotrophic Lateral Sclerosis after Nuedexta (Dextromethorphan and Quinidine) Treatment
- Affiliations
-
- 1Department of Neurology, Kyungpook National University Chilgok Hospital, Daegu, Korea. jinforeva@gmail.com
- 2Department of Neurology, Dongguk University College of Medicine, Gyeongju, Korea.
- 3Department of Neurology, School of Medicine, Kyungpook National University, Daegu, Korea.
- KMID: 2454844
- DOI: http://doi.org/10.17340/jkna.2019.2.9
Abstract
- Nuedexta (dextromethorphan and quinidine) is an Food and Drug Administration approved medication for pseudobulbar affect. Interestingly, this drug was recently reported to improve speech, swallowing, and the ability to handle oral secretions along with emotional lability in amyotrophic lateral sclerosis (ALS) patients with bulbar symptoms. We report a Korean ALS patient whose bulbar function improved after administering Nuedexta for 6 months, extending therapeutic choice of approach in treating ALS patients.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Syndrome of Progressive Bulbar Palsy in Amyotrophic Lateral Sclerosis: A Case Report
- Effect of Serum Perampanel Concentration on Sporadic Amyotrophic Lateral Sclerosis Progression
- Amyotrophic Lateral Sclerosis Associated With CADASIL
- Apraxia of Eyelid Closure and Motor Impersistence of Eyelid in a Patient with Amyotrophic Lateral Sclerosis
- Psychosocial Responses and Quality of Life among Amyotrophic Lateral Sclerosis Patients and Their Caregivers
